Back to search results
NCT07594665

Expanding Access to Cognitive Health Biomarker Testing at Home

Enrolling by Invitation
Not specifiedAges 65+Observational
University of Virginia
~100 participants
Updated 2026-05-19 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acceptability of remote, at-home p-tau217 workflow
Measured over From enrollment through study completion (~7 months)
+1 more outcome measured

Conditions

Mild Cognitive Impairment (MCI)
Alzheimer's Dementia (AD)
Subjective Cognitive Decline (SCD)
Cognitive Aging

Explore related trials

Mild cognitive disorderSubjective Cognitive Decline

NCT07594665

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Virginia, School of Nursing

    Charlottesville, Virginiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged 65 years or older
Active participant in the SHUTi MIND parent study (UVA IRB-HSR #220077)
US resident
Able to read and speak English
Regular access (at least twice weekly) to and willingness to use a computer and the Internet, including email
Endorsement of subjective cognitive concerns or possible mild cognitive impairment, based on TICS screening
Completed the 24-month post-assessment for the SHUTi MIND study, or at least 90 days since the post-24-month assessment was due

Exclusion

Severe cognitive impairment that would preclude informed consent or completion of study procedures
Inability or unwillingness to perform at-home capillary blood collection or to participate in remote results disclosure
No cognitive concerns

What this trial measures

  • Acceptability of remote, at-home p-tau217 workflowFrom enrollment through study completion (~7 months)

    Participant-reported acceptability of the fully remote at-home p-tau217 testing and disclosure workflow, measured by a standardized post-disclosure acceptability questionnaire assessing perceived ease of use of the Tasso device, comfort with at-home blood collection, satisfaction with remote results disclosure, perceived burden, and willingness to recommend the workflow to others.

  • End-to-end remote workflow completion rateFrom enrollment through study completion (~7 months)

    Proportion of enrolled participants who complete each step of the fully remote workflow: kit receipt, at-home capillary blood collection using the blood-collection device, return shipment within the time window required for sample stability, and completion of remote results disclosure by a board-certified neurologist.